Physiomics PLC Agreement with Bicycle and Cancer Research UK

Data : 08/07/2019 @ 03:00
Fonte : RNS Non-Regulatory
Ativo : Physiomics Plc (PYC)
Cotação : 2.75  0.1 (3.77%) @ 08:00
Cotação Gráfico

Physiomics PLC Agreement with Bicycle and Cancer Research UK

TIDMPYC

Physiomics PLC

08 July 2019

8 July 2019

Physiomics plc

("Physiomics") or (the "Company")

Physiomics signs agreement with Bicycle Therapeutics and Cancer Research UK

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK. The project is expected to be completed during this calendar year and will focus on the analysis of clinical data arising from the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial of Bicycle Therapeutics' lead program, BT1718, in solid tumours.

Dr Jim Millen, CEO said: "We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAEADXSESPNEFF

(END) Dow Jones Newswires

July 08, 2019 02:00 ET (06:00 GMT)

Physiomics (LSE:PYC)
Gráfico Histórico do Ativo

1 Ano : De Out 2018 até Out 2019

Click aqui para mais gráficos Physiomics.

Physiomics (LSE:PYC)
Gráfico Intraday do Ativo

Hoje : Terça, 22 de Outubro de 2019

Click aqui para mais gráficos Physiomics.
Seu Histórico Recente
BOV
VALE5
Vale PNA
BOV
IBOV
iBovespa
BOV
PETR4
Petrobras
BOV
IGBR3
IGB SA
FX
USDBRL
Dólar EUA ..
Ações já vistas aparecerão nesta caixa, facilitando a volta para cotações pesquisadas anteriormente.

Registre-se agora para criar sua própria lista de ações customizada.

Cotações da NYSE e AMEX têm defasagem de no mínimo 20 minutos.
Quaisquer outras cotações têm defasagem de no mínimo 15 minutos quando não especificado.
Em caso de dúvidas por favor entre em contato com o suporte: suporte@advfn.com.br ou (11) 4950 5808.
P: V:br D:20191023 00:07:52